What is Zacks Research’s Estimate for PBH Q1 Earnings?

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Analysts at Zacks Research lowered their Q1 2027 earnings estimates for shares of Prestige Consumer Healthcare in a report released on Tuesday, February 24th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $1.09 for the quarter, down from their prior forecast of $1.24. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s FY2027 earnings at $4.77 EPS, Q2 2028 earnings at $1.30 EPS, Q3 2028 earnings at $1.26 EPS and FY2028 earnings at $5.06 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The firm had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company’s quarterly revenue was down 2.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.22 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS.

PBH has been the topic of several other reports. Jefferies Financial Group reduced their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th. Canaccord Genuity Group reduced their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $80.60.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $69.30 on Friday. The company has a market cap of $3.28 billion, a PE ratio of 18.33, a price-to-earnings-growth ratio of 2.21 and a beta of 0.43. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. The stock has a 50-day moving average price of $65.26 and a two-hundred day moving average price of $63.48. Prestige Consumer Healthcare has a 12-month low of $57.25 and a 12-month high of $90.04.

Insider Transactions at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00. Following the sale, the vice president owned 41,048 shares in the company, valued at $2,706,294.64. This trade represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its stake in Prestige Consumer Healthcare by 4.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company’s stock worth $161,723,000 after buying an additional 119,459 shares during the period. State Street Corp boosted its position in Prestige Consumer Healthcare by 1.4% in the 4th quarter. State Street Corp now owns 1,992,497 shares of the company’s stock valued at $122,917,000 after buying an additional 27,721 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Prestige Consumer Healthcare by 1.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock valued at $98,776,000 after acquiring an additional 21,085 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Prestige Consumer Healthcare by 0.7% during the second quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock valued at $112,843,000 after acquiring an additional 9,455 shares in the last quarter. Finally, Morgan Stanley increased its position in shares of Prestige Consumer Healthcare by 6.3% during the fourth quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock worth $74,209,000 after acquiring an additional 71,078 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare News Summary

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Bleakley Financial Group reported a new purchase of 10,912 PBH shares (~$681,000), signaling fresh institutional buying interest in the stock. Bleakley Investment
• Positive Sentiment: Zacks bumped a few quarterly estimates: Q4 2026 was raised to $1.59 (from $1.54), Q3 2027 to $1.21 (from $1.20) and Q4 2027 to $1.32 (from $1.26) — small upside revisions that suggest pockets of strength in certain quarters.
• Neutral Sentiment: Zacks Research continues to carry a “Hold” rating on PBH even as it updates estimates; the firm’s commentary so far is a recalibration of numbers rather than a rating change. Consensus full‑year EPS referenced by Zacks remains near $4.50 for the current year.
• Negative Sentiment: Zacks pared several near‑term and fiscal forecasts, which is the main driver of downward pressure: Q1 2027 EPS cut to $1.09 (from $1.24), Q1 2028 to $1.14 (from $1.26), Q2 2028 to $1.30 (from $1.33), Q3 2028 to $1.26 (from $1.28), FY2027 to $4.77 (from $4.84) and FY2028 to $5.06 (from $5.19). Those trims signal slower expected earnings growth and likely explain why the stock is underperforming today.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).